

Disclaimer

This presentation contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. The Group is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.


The availability and indications/claims of the products illustrated and mentioned in this presentation may vary according to country.

Today's announcement in a nutshell

- Group plans a 9% reduction in its global workforce this year to align costs with lower revenues due to pandemic and recession
- Straumann commits to managing the reduction process in a responsible, timely and fair manner
- Business fundamentals remain valid; resizing will not compromise company's ability to innovate, manufacture, supply and sell winning solutions, nor to bounce back quickly and strongly


Dental practices taking time to open for non-essential treatments

Status: 11 May 2020 (major countries)



Strong momentum interrupted – recession will prolong time to recovery

Straumann Group organic growth




Recovery scenarios


GDP Q1 2020 (vs. prior quarter)

China: - 9.8%¹

EU: - 3.8 %²


USA: - 4.8 %³








Three phases characterizing the Covid-19 journey



Organization has been geared for continuation of strong growth and must be aligned quickly to lower sales

Workforce doubled over past 3 years to approx. 7680



Poised to bounce back strongly

- We are taking necessary action sooner rather than later; liquidity ensured; costs and production capacity adapted to future demand
- 2020: high double-digit million savings expected, incl. personnel reductions & restructuring costs of approx. CHF 15m; 2021: expected savings from personnel reductions of approx. CHF 30m
- Our implant portfolio is unparalleled and covers all price levels in key markets
- We have a strong rollout pipeline, including state-of-the art digital solutions, BLX, Virtuo Vivo, Smile
 in a Box, ClearCorrect etc; we have everything we need to become a leader in immediacy
- We have been using the lock-down to gain and train customers highly successful online initiatives generate >200 000 visits and >20 000 customer leads
- Business fundamentals remain valid; resizing will protect our ability to innovate, manufacture, supply and sell winning solutions, and to bounce back quickly and strongly
- With a winning, agile culture and a resized team of 7000, we still are the driving force in our field

Questions & answers



